H.C. Wainwright downgraded Tracon Pharmaceuticals to Neutral from Buy and removed the firm’s prior price target after the company announced that the objective response rate by blinded independent central review of 5%in the ENVASARC Phase 2 trial did not reach the primary endpoint. Following the results, the firm no longer includes envafolimab in its valuation, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCON:
- TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
- TRACON Pharmaceuticals Announces Executive Officer Resignation
- Biotech Alert: Searches spiking for these stocks today
- Tracon Pharmaceuticals announces publication of Phae 2 data for TRC102
- TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients